The estimated Net Worth of Alison L. Hannah is at least $818 Тысяча dollars as of 10 August 2024. Dr Hannah owns over 11,336 units of CytomX Therapeutics Inc stock worth over $155,587 and over the last 9 years he sold CTMX stock worth over $7,955. In addition, he makes $654,563 as Sr. VP & Chief Medical Officer at CytomX Therapeutics Inc.
Dr has made over 9 trades of the CytomX Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 11,336 units of CTMX stock worth $14,850 on 10 August 2024.
The largest trade he's ever made was buying 20,000 units of CytomX Therapeutics Inc stock on 27 July 2017 worth over $183,800. On average, Dr trades about 3,303 units every 110 days since 2015. As of 10 August 2024 he still owns at least 118,769 units of CytomX Therapeutics Inc stock.
You can see the complete history of Dr Hannah stock trades at the bottom of the page.
Dr. Alison L. Hannah M.D. is the Sr. VP & Chief Medical Officer at CytomX Therapeutics Inc.
As the Sr. VP & Chief Medical Officer of CytomX Therapeutics Inc, the total compensation of Dr D at CytomX Therapeutics Inc is $654,563. There are 6 executives at CytomX Therapeutics Inc getting paid more, with Sean McCarthy having the highest compensation of $3,769,930.
Dr D is 60, he's been the Sr. VP & Chief Medical Officer of CytomX Therapeutics Inc since . There are 7 older and 11 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
Alison's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca... и James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: